NEW YORK (GenomeWeb News) – Sangamo BioSciences today announced that it has entered into a licensing agreement with Palo Alto, Calif.-based Open Monoclonal Technologies, under which OMT obtained non-exclusive, worldwide rights to develop transgenic animals using Sangamo’s proprietary zinc finger DNA-binding technology.
In exchange, Richmond, Calif.-based Sangamo will receive an upfront license fee, future payments contingent on clinical development milestones, a share of payments that OMT receives from its sub-licensees, and royalties on sale’s related to the ZFP technology.
OMT will have the right to buy out these royalty payments with a lump sum payment for each OMT product. Other financial details of the agreement were not disclosed.
Zinc finger DNA-binding proteins belong to a group of proteins called transcription factors that bind DNA and help regulate its expression in the cell. Sangamo’s engineered ZFPs and sequence specific ZFP nucleases (ZFN) are designed to precisely modify the genes to which they bind.
Applying this technology to transgenic animal research may improve the ease and efficiency of generating site-specific mutations in animal models. This approach, in turn, could broaden transgenic animal research beyond the traditional mouse model, Sangamo Vice President of Research Philip Gregory said in a statement.
“The frequency and precision of ZFN-mediated genome-editing, in combination with the ability to design ZFNs against potentially any gene, opens up the potential to more easily generate transgenic animals of any species,” Gregory said.